Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 2
2009 1
2013 1
2014 3
2016 1
2017 4
2018 6
2019 9
2020 12
2021 15
2022 18
2023 18
2024 11
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: takeda t. Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613731 Free PMC article.
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.
Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T, Takeda T, Shirasaki H, Nishi K, Sone T, Yamada T, Takayama K, Shibata K, Matsuoka H, Kita T, Nagata K, Tambo Y, Ohkura N, Hara J, Kasahara K, Kohsaka S, Mano H, Yano S. Terada N, et al. Among authors: takeda t. Transl Lung Cancer Res. 2024 Nov 30;13(11):3067-3082. doi: 10.21037/tlcr-24-471. Epub 2024 Nov 28. Transl Lung Cancer Res. 2024. PMID: 39670006 Free PMC article.
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Shimose T, Takayama K. Kawachi H, et al. Among authors: takeda t. Oncoimmunology. 2025 Dec;14(1):2442116. doi: 10.1080/2162402X.2024.2442116. Epub 2024 Dec 16. Oncoimmunology. 2025. PMID: 39681395 Free PMC article.
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: takeda t. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762. Clin Cancer Res. 2025. PMID: 39495173
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: takeda t. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Malignant pleural mesothelioma with heterologous elements.
Kawai T, Seki R, Miyajima K, Nakashima H, Takeda T, Murakami T, Aoe K, Okabe K, Homma K, Tsukamoto Y, Sunada K, Terasaki Y, Iida M, Orikasa H, Hiroshima K. Kawai T, et al. Among authors: takeda t. J Clin Pathol. 2021 Aug 10:jclinpath-2021-207575. doi: 10.1136/jclinpath-2021-207575. Online ahead of print. J Clin Pathol. 2021. PMID: 34376566
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Kunimatsu Y, Nishioka N, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Kijima T, Takayama K. Kunimatsu Y, et al. Among authors: takeda t. Transl Lung Cancer Res. 2025 Nov 30;14(11):4733-4745. doi: 10.21037/tlcr-2025-873. Epub 2025 Nov 27. Transl Lung Cancer Res. 2025. PMID: 41367575 Free PMC article.
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: takeda t. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
IgG4-related lung disease progressing to respiratory failure.
Kunimatsu Y, Tani N, Sato I, Ogura Y, Hirose K, Takeda T. Kunimatsu Y, et al. Among authors: takeda t. Respirol Case Rep. 2020 Aug 11;8(7):e00641. doi: 10.1002/rcr2.641. eCollection 2020 Oct. Respirol Case Rep. 2020. PMID: 32789018 Free PMC article.
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Katayama Y, Yamada T, Sawada R, Kawachi H, Morimoto K, Watanabe S, Watanabe K, Takeda T, Chihara Y, Shiotsu S, Hibino M, Harada T, Nishioka N, Iwasaku M, Tokuda S, Takayama K. Katayama Y, et al. Among authors: takeda t. Oncologist. 2024 May 3;29(5):e681-e689. doi: 10.1093/oncolo/oyae001. Oncologist. 2024. PMID: 38241181 Free PMC article.
99 results